在临床前研究中治疗炎症性肠病的白醇:系统性审查和元分析
Yuting Gu1, Yijie Lou1, Zhanyi Zhou1
1The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Frontiers in pharmacology
|July 1, 2024
概括
复星在动物模型中显示了炎症性肠病 (IBD) 的治疗潜力. 较高剂量 (>80 mg/kg) 在减少炎症和改善肠道健康方面表现出显著的有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 自然产品 自然产品
背景情况:
- 炎症性肠病 (IBD) 是一种慢性疾病,治疗方法有限.
- 植物性聚醇resveratrol正在研究其在IBD中的治疗潜力.
- 目前的研究重点是评估白醇在临床前IBD模型中的疗效.
研究的目的:
- 系统地审查和对白醇在IBD动物模型上的治疗效果进行元分析.
- 评估复星对胰腺病理指数和其他IBD相关生物标志物的影响.
- 确定白醇在IBD治疗中的最佳剂量和潜在作用机制.
主要方法:
- 在多个数据库 (PubMed,Embase,Web of Science,中国数据库) 进行了全面的文献搜索.
- 使用CAMARADES检查清单进行了偏差风险评估.
- 使用Review Manager 5.4进行了元分析,以基因病理指数为主要结果,并补充了子组分析和评估其他参数,如疾病活动指数,体重,结肠长度,脏指数和炎症因素.
主要成果:
- 包括28项研究,其中大多数显示偏差风险低.
- 与对照组相比,resveratrol在IBD模型中显著降低了组织病理指数 (WMD = -2.58).
- 较高剂量 (>80 mg/kg) 显示出更高的疗效 (WMD = -3.47),肠粘膜损伤,结肠长度和关键炎症因子 (IL-1β,IL-6,TNF-α等) 的调节显著改善. 和氧化应激标志物 (MDA,SOD).
结论:
- 复星在临床前IBD模型中显示出显著的治疗效果,特别是在超过80mg/kg的剂量时.
- 它的有效性与向肠道粘膜的保护机制有关,涉及免疫反应调节和氧化应激的抑制.
- 复星在治疗IBD方面显示出未来临床应用的有希望的潜力.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Inflammatory Bowel Disease V: Surgical Management
139
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
139


